Sign In
29 May 2019 11:07
Â
Verona Pharma plc
PDMR Dealing
Â
May 29, 2019, LONDON - Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) ("Verona Pharma"), a biopharmaceutical company focused on respiratory diseases, announces that, on May 28, 2019, Kayt Morgan, spouse of Mr. Piers Morgan, CFO of the Company, purchased 33,802 ordinary shares of 5 pence each in the Company (the "Ordinary Shares") at a price of 59 pence per Ordinary Share and a total purchase price of ÂŁ19,954.18. Following the acquisition, Mr. Morgan will have a beneficial interest in the Company of 147,009 Ordinary Shares, representing 0.14% of the Company's issued share capital.
This purchase brings the total purchases by Mr. and Mrs. Morgan during the past few months to over ÂŁ52,000 and follows the purchases made by the Company's Chairman, Dr. David Ebsworth, in March totaling approximately ÂŁ50,000.
The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.
Â
1 | Details of the person discharging managerial responsibilities/person closely associated | |
a) | Name  | Kayt Morgan |
2 | Reason for the notification | |
a) | Position/status  | Spouse (PCA) of Piers Morgan, Chief Financial Officer |
b) | Initial notification/Amendment  | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Verona Pharma plc |
b) | LEI Â | 213800EVI6O6J3TIAL06 Â |
Â
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of 5 pence each GB00BYW2KH80 | ||||
b) | Nature of the transaction  | Purchase of Ordinary Shares | ||||
c) | Price(s) and volume(s) Â Â |
| ||||
d) | Aggregated information - Aggregated volume - Price | N/A Â | ||||
e) | Date of the transaction | 28 May 2019 | ||||
f) | Place of the transaction | London Stock Exchange, AIM | ||||
Â
Â
Â
For further information, please contact:
Â
Verona Pharma plc | Tel: +44 (0)20 3283 4200 |
Jan-Anders Karlsson, Chief Executive Officer Victoria Stewart, Director of Communications | info@veronapharma.com |
N+1 Singer (Nominated Adviser and UK Broker) | Tel: +44 (0)20 3283 4200 Â |
Aubrey Powell /Jen Boorer /Iqra Amin (Corporate Finance) Mia Gardner (Corporate Broking) |
Â
Follow the stocks
